ERBB3 and breast cancer: Some studies have shown that activation of the signaling pathways initiated by other HER family members, such as EGFR and HER3, or non-HER receptors, including AXL, limits the response of HER2-positive BC cells to both trastuzumab and lapatinib [14–18].